Abstract Body

The rapid diagnosis of HCV infection is hampered by slow antibody responses and lack of reliable point-of-care tests (POCT). In addition, patients often report preferring blood collection by finger-prick rather than by venous puncture. The Cepheid GeneXpert platform provides a closed system for nucleic acid amplification and detection that makes it suitable for use outside of specialized laboratory settings including POCT; however, there are no published data on the use of small volume capillary blood for HCV RNA detection. This study assessed the performance of the GeneXpert HCV RNA assay in paired blood samples collected by venous puncture and by finger-prick in subjects with known HCV and HIV status.

Capillary blood was collected by nursing staff using the Roche Accu-Chek Safety Safe-T-Pro Plus Lancet and the Sarstedt Microvette® 100 K3E following established finger-prick procedure. Venous blood was collected in EDTA tubes. The assay was run blind by laboratory staff. Capillary blood (100μl) was transferred directly to the assay cartridge followed by 1ml Xpert diluent. In parallel, plasma (1.1 ml) separated from venous blood was added to another cartridge without sample diluent. Both cartridges were run on the GeneXpert XVI analyzer according to the manufacturer’s instructions. Serial dilutions (2-5 log10 IU/ml) of plasma from two HCV RNA positive patients (HCV genotype 1a and 3a) were tested in duplicate to verify sensitivity of the 100ul protocol.

Of 35 subjects undergoing paired blood collection by finger-prick and venous puncture, 2 were excluded due to insufficient sample and cartridge error, respectively. Of the remaining 33 subjects, 24 were HCV antibody and RNA positive, including 5 that were co-infected with HIV. Their plasma HCV RNA load was median 6.0 log10 IU/ml (IQR 5.5-6.4) and HCV genotypes were 1a, 3a, 1b, and 4. A total of 9 subjects were HCV antibody and RNA negative. In all subjects, results obtained with capillary blood matched those of venous blood, and both were in agreement with the patients’ known HCV status. With the serial dilutions, the assay showed good linearity (R2 ≥0.99) and 100% detection rate at 2 log10 IU/ml.

The data support the use of small volume capillary blood for HCV RNA detection by GeneXpert, and provide the evidence base for studies evaluating use as POCT in non-specialist laboratory settings.